Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merck & Co Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MRK
New York
2834
https://www.merck.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merck & Co Inc
Merck (MRK) Rises Higher Than Market: Key Facts
- Mar 28th, 2024 9:50 pm
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
- Mar 28th, 2024 1:40 pm
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
- Mar 28th, 2024 1:15 pm
Company News for Mar 28, 2024
- Mar 28th, 2024 11:15 am
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
- Mar 28th, 2024 10:45 am
US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight
- Mar 27th, 2024 8:36 pm
US STOCKS-Stocks gain, led by Dow as investors look for rate insight
- Mar 27th, 2024 8:00 pm
US STOCKS-Dow leads gains on Wall Street as investors await rate clues
- Mar 27th, 2024 6:58 pm
FDA approves Merck treatment for lung disease, potential path to upside
- Mar 27th, 2024 2:58 pm
US STOCKS-Dow leads Wall St higher in lean trading week
- Mar 27th, 2024 2:10 pm
Merck Drug for Rare Form of High Blood Pressure Gets US Nod
- Mar 27th, 2024 1:53 pm
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
- Mar 27th, 2024 1:00 pm
US STOCKS-Wall St set to open higher as growth stocks recover
- Mar 27th, 2024 12:50 pm
US STOCKS-Futures tick up in thin trading week, Fed commentary in focus
- Mar 27th, 2024 11:36 am
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
- Mar 26th, 2024 10:21 pm
Merck’s $11.5 Billion Bet on Its Next Big Drug Finally Arrives
- Mar 26th, 2024 9:07 pm
FDA approves Merck lung disease drug acquired in $11B deal
- Mar 26th, 2024 5:12 pm
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
- Mar 26th, 2024 1:30 pm
20 Biggest Health Care Companies in Australia, 2024
- Mar 26th, 2024 9:15 am
Is Merck (NYSE:MRK) A Risky Investment?
- Mar 25th, 2024 12:00 pm
Scroll